Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

References

• Morrison-Griffiths S, Gaulton L. Seasonal influenza immunization program outside general practice: an evaluation. Hum Vaccin Immunother. 2016;12(1):248–51. PMID:26566596. doi:10.1080/21645515.2015.1099770.
   PubMed Web of Science ®Google Scholar
• Swaan CM, van der Sande MA, Speelman P, Conyn-van Spaendonck MA, Straus SM, Coutinho RA. Adverse events following influenza vaccination: reaction to specific reports and the necessity of a central registration system. Ned Tijdschr Geneeskd. 2007; 29; 151(39):2166–69. PMID:17957995.
   PubMedGoogle Scholar
• Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The developing countries vaccine manufacturers’ network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine. 2008;26:1611–15. doi:10.1016/j.vaccine.2008.01.034.
   PubMed Web of Science ®Google Scholar
• Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W. An international technology platform for influenza vaccines. Vaccine. 2011;29(1):A8–11. PMID:21684431. doi:10.1016/j.vaccine.2011.04.124.
   PubMedGoogle Scholar
• Haugh M, Gresset-Bourgeois V, Macabeo B, Woods A, Samson SI. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Rev Vaccines. 2017;16(6):545–64. PMID:28460594. doi:10.1080/14760584.2017.1324302.
   PubMed Web of Science ®Google Scholar
• Sokolova TM, Shuvalov AN, Poloskov VV, Shapoval IM, Kostinov MP. Grippol, Vaxigrip and influvac vaccines – inductors of innate and adaptive immunity factor genes in human blood cells. Zh Mikrobiol Epidemiol Immunobiol. 2014;(5):37–43. PMID:25536769.
   PubMedGoogle Scholar
• WHO. Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Drug Saf. 2015;38(11):1059–74. PMID:26446142. doi:10.1007/s40264-015-0350-4.
   Google Scholar
• Petrovsky N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 2015;38(11):1059–74. PMID:26446142. doi:10.1007/s40264-015-0350-4.
   PubMed Web of Science ®Google Scholar
• Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y. PHAC/CIHR Influenza Research Network (PCIRN). Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine. 2012; 6; 30(32):4728–32. PMID:22652402. doi:10.1016/j.vaccine.2012.05.029.
   PubMed Web of Science ®Google Scholar
• Levine M, Beattie BL, McLean DM, Corman D. Characterization of the immune response to trivalent influenza vaccine in elderly men. J Am Geriatr Soc. 1987;35:609–15. doi:10.1111/j.1532-5415.1987.tb04335.x.
   PubMed Web of Science ®Google Scholar
• Mamadaliyev SM, Sandybayev NT, Kydyrbayev ZK, Khairullin BM, Zaitsev VL, Mambetaliev M, Kassenov MM, Chervyakova OV, Ryskeldinova S, Volgin YN, et al. Development of production technology and pre-clinical testing of a pandemic influenza A⁄H1N1 vaccine. Influenza Other Respir Viruses. 2011;5(1):354–57.
   Google Scholar
• Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, et al. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/chicken/astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol. 2013;20:1314–19. PMID:23803900. doi:10.1128/CVI.00096-13.
   PubMed Web of Science ®Google Scholar
• Mamadaliyev SM, Sandybayev NT, Kydyrbayev ZK, Khairullin BM, Zaitsev VL, Mambetaliev M, Kassenov MM, Chervyakova OV, Ryskeldinova S, Volgin YN, et al. Basic results of development of a production technology and control of a pandemic influenza A/H5N1 vaccine. Influenza Other Respir Viruses. 2011;5(1):350–53.
   Google Scholar
• Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Nurpeissova A, Sagymbay A, Abitay R, Stukova M, Khairullin B, et al. A novel preservative-free seasonal influenza vaccine safety and immune response studying in the frame of preclinical research. J Med Virol. 2017;9999:1–6. doi:10.1002/jmv.24771.
   Google Scholar
• Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Abitay R, Nurpeisova A, Sagymbay A, Koshemetov Z, et al. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized, and placebo-controlled trial. J Med Virol. 2017;1–9. doi:10.1002/jmv.24922.
   Web of Science ®Google Scholar
• Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, et al. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: results of a randomized, comparative, phase II clinical trial in adults. Hum Vaccin Immunother. 2018;14:609–14. doi:10.1080/21645515.2017.1387345.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Note for guidance on harmonisation of requirements for influenza vaccines. 1997 [accessed 2017 May 9]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
   Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86. PMID: 12517228. doi:10.1001/jama.289.2.179.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012;30:2060–67. PMID: 22289511. doi:10.1016/j.vaccine.2012.01.015.
   PubMed Web of Science ®Google Scholar
• Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. In Vaccines for Pandemic Influenza, RW Compans and WA Orenstein (eds). Curr Top Microbiol Immunol. 2009;333:413–29. doi:10.1007/978-3-540-92165-3_20.
   PubMedGoogle Scholar
• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25:3066–69. PMID: 17275144. doi:10.1016/j.vaccine.2007.01.025;.
   PubMed Web of Science ®Google Scholar
• Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel). 2003;115:9–16. PMID: 15088770.
   PubMedGoogle Scholar